ReviewCancers2022
Orchidaceae-Derived Anticancer Agents: A Review.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 38 citations in OpenAlex.
- Theoretical visualization of covalent and non-covalent interactions: molecular diversity and substituent effects governing the reactivity of Bulbophyllum bibenzyl derivatives.Molecular diversity · 2026Article
- Enhancing Targeted Colorectal Cancer Therapies with Natural Products: Mechanistic Pathways.Biomedicines · 2026Review
- Efficient plant regeneration via protocorm-like body induction from stem nodes in Anoectochilus roxburghii (Wall.) Lindl.BMC plant biology · 2026Article
- Preventive effects ofBiomedical reports · 2026Article
- Differential Metabolic Analysis of Rhizomes in Shancigu Based on Widely Targeted Metabolomics.Metabolites · 2025Article
- Antitumor Activity of Isalpinin fromMolecules (Basel, Switzerland) · 2025Article
- Antioxidant and cytotoxic properties of protocorm-derived phenol-rich fractions of Dendrobium amoenum.BMC complementary medicine and therapies · 2025Article
- UGT708S6 from Dendrobium catenatum, catalyzes the formation of flavonoid C-glycosides.BMC biotechnology · 2024Article
- New Phenolic Glycosides fromACS omega · 2024Article
- Cymensifin A: a promising pharmaceutical candidate to defeat lung cancer via cellular reactive oxygen species-mediated apoptosis.Frontiers in pharmacology · 2024Article
- Influence of phytocenosis on the medical potential of moss extracts: the Pleurozium schreberi (Willd. ex Brid.) Mitt. case.Scientific reports · 2023Article
- Article
- Anticancer and chemosensitizing activities of stilbenoids from three orchid species.Naunyn-Schmiedeberg's archives of pharmacology · 2023Article
- Analysis of metabolites and metabolism-mediated biological activity assessment of ginsenosides on microfluidic co-culture system.Frontiers in pharmacology · 2023Article
- Pharmacological and Chemical Potential ofPlants (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Species of orchids, which belong to the largest family of flowering plants, are commonly used in folk medicine for the treatment of infections and tumors. However, little is known about the actual chemical composition of these plants and their anticancer properties. In this paper, the most recent literature on orchid-derived bioactive substances with anticancer properties is reviewed. For the assessment, previous papers on the anticancer activity of Orchidaceae published since 2015 were considered. The papers were found by exploring electronic databases. According to the available data, many species of orchids contain potential antitumor chemicals. The bioactive substances in a relatively insignificant number of orchids are identified, and most studies are on Asian taxa. Broader research on American and African species and the correct identification of samples included in the experiments are essential for evaluating the usefulness of orchids as a plant family with vast anticancer potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.